RBC Capital Reiterates Underperform on Pfizer, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Negative 96.0%

Neg 96% Neu 0% Pos 0%

RBC Capital analyst Trung Huynh reiterates Pfizer (NYSE:PFE) with a Underperform and maintains $25 price target.

Comments

No comments yet. Be the first!